Moreover, we reported that phosphodiesterase 5 (PDE5) inhibition synergistically enhanced the anticancer effect of EGCG in multiple myeloma (14) and acute myeloid leukemia cells (33). The gene discussed is PDE5A; the disease is plasma cell myeloma.